ClinicalTrials.gg
CompletedNCT02569242Updated Jul 6, 2022Results posted

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

A Phase 3 interventional study of Nivolumab and Docetaxel/Paclitaxel in Esophageal Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 89 sites in 8 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
419
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing nivolumab in Esophageal Neoplasms — 4 open to participants now, 11 under way, none of them phase 3. Nivolumab · Esophageal Neoplasms.

Enrollment
3rd of 18
419 · median 49
Started
2015
with 1 other
Phase 3
Only one
of the 18
Registered
2nd of 18
by date

Among the 18 studies testing nivolumab in Esophageal Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is the only one in phase 3, and was the 2nd registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

4 of the 18 studies testing nivolumab in Esophageal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing nivolumab in Esophageal Neoplasms, or all of them as a file.
02

Study summary

The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.

03

Conditions studied

  • Esophageal Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men \& women ≥20 years of age
  • confirmed unresectable advanced or recurrent esophageal cancer
  • to or intolerant of standard therapy
  • Performance Status score 0 or 1
  • A of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Current or past history of severe to any other antibody products
  • Patients with multiple primary cancers
  • Patients with any in the brain or meninx that is symptomatic or requires treatment
  • Patients with active, known or suspected disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
419 participants (actual)

Study arms

  • Experimental
    Nivolumab Arm

    Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

    Drug: Nivolumab

  • Active comparator
    Active Comparator Arm (Docetaxel/Paclitaxel)

    Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends OR Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

    Drug: Docetaxel/Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: ("Date of death from any cause" - "Date of randomization" + 1) / 30.4375. For subjects lost to follow-up and subjects who are alive at the time of data cutoff date, data will be censored at the time the subject was last confirmed to be alive.

Secondary outcomes

  1. Progression-free Survival

    Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."

    Time frame: ("Earlier date on which either the overall response was assessed as PD or the subject died of any cause" - "Date of randomization" + 1) / 30.4375.

  2. Duration of Response

    Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."

    Time frame: ("Earlier date on which either the overall response was assessed as PD for the first time after confirmed response or the subject died of any cause" - "Date of first assessment of confirmed CR or PR" + 1) / 30.4375.

07

Results

Posted Jan 14, 2022

Participant flow

Participant flow — Overall Study
MilestoneNivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)
Started210209
Completed209208
Not completed11
Withdrew: Death10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryOverall Survival
Time frame:
("Date of death from any cause" - "Date of randomization" + 1) / 30.4375. For subjects lost to follow-up and subjects who are alive at the time of data cutoff date, data will be censored at the time the subject was last confirmed to be alive.
Reported as:
Median · months
Overall Survival
monthsNivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)
Overall Survival10.9 (9.2 to 13.3)8.4 (7.2 to 9.9)
SecondaryProgression-free Survival

Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."

Time frame:
("Earlier date on which either the overall response was assessed as PD or the subject died of any cause" - "Date of randomization" + 1) / 30.4375.
Reported as:
Median · months
Progression-free Survival
monthsNivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)
Progression-free Survival1.7 (1.5 to 2.7)3.4 (3.0 to 4.2)
SecondaryDuration of Response

Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."

Time frame:
("Earlier date on which either the overall response was assessed as PD for the first time after confirmed response or the subject died of any cause" - "Date of first assessment of confirmed CR or PR" + 1) / 30.4375.
Reported as:
Median · months
Duration of Response
monthsNivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)
Duration of Response6.9 (5.4 to 11.1)3.9 (2.8 to 4.2)

Adverse events

Collected over Monitoring for any AEs will be continued until 28 days after the end of the treatment phase. In subjects who, at the time of initiation of the follow-up investigation, have any AE for which a causal relationship to the investigational product cannot be ruled out or which led to discontinuation, investigation of the AE will be continued until the event is judged not to require further follow-up. SAEs are to be collected during the treatment period and for 100 days following the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab Arm7/209 (3.3%)68/209 (32.5%)185/209 (88.5%)
Active Comparator Arm (Docetaxel/Paclitaxel)5/208 (2.4%)77/208 (37%)204/208 (98.1%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventNivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)
Febrile neutropeniaBlood and lymphatic system disorders0/20916/208
PneumoniaInfections and infestations10/20913/208
Decreased appetiteMetabolism and nutrition disorders3/2096/208
PyrexiaGeneral disorders6/2091/208
Lung infectionInfections and infestations1/2095/208
HypercalcaemiaMetabolism and nutrition disorders4/2091/208
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders4/2093/208
Neutrophil count decreasedInvestigations0/2093/208
Pleural effusionRespiratory, thoracic and mediastinal disorders1/2093/208
PneumonitisRespiratory, thoracic and mediastinal disorders3/2093/208
Most frequent other events
Showing 10 of 35
Most frequent other events
EventNivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)
AlopeciaSkin and subcutaneous tissue disorders3/209100/208
Neutrophil count decreasedInvestigations3/20976/208
White blood cell count decreasedInvestigations2/20972/208
Decreased appetiteMetabolism and nutrition disorders40/20968/208
AnaemiaBlood and lymphatic system disorders24/20961/208
FatigueGeneral disorders19/20952/208
MalaiseGeneral disorders12/20949/208
Peripheral sensory neuropathyNervous system disorders1/20948/208
NeutropeniaBlood and lymphatic system disorders1/20940/208
ConstipationGastrointestinal disorders35/20940/208

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
<=18 years000
Between 18 and 65 years11285197
>=65 years98124222
Age, Continuous
Age, Continuous(years)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
Mean64 (57 to 69)67 (57 to 72)65 (57 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
Female312455
Male179185364
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
American Indian or Alaska Native000
Asian201200401
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9918
More than one race000
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
Asian201200401
White9918
ECOG performance status
ECOG performance status(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
0101107208
1109102211
Disease stage : TNM classification
Disease stage : TNM classification(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
II - III81321
IV94100194
unknown5712
Previous therapies
Previous therapies(Participants)Nivolumab ArmActive Comparator Arm (Docetaxel/Paclitaxel)Total
Surgery11194205
Radiothrapy153142295
Systemic anticancer therapy210208418

4 further baseline measures are reported on the registry.

08

Study locations

89 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Georgetown University Med Ctr
    Washington, District of Columbia 20007, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Vanderbilt-Ingram Cancer Ctr
    Nashville, Tennessee 37232, United States
  • The University Of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Odense University Hospital
    Odense C, 5000, Denmark
  • RWTH Aachen University
    Aachen, 52057, Germany
  • Charite Campus Virchow Klinikum
    Berlin, D-13353, Germany
  • University Hospital Heidelberg
    Heidelberg, 69120, Germany
  • Universitatsklinikum Jena, Innere Medizin II
    Jena, 07747, Germany
  • MVZ Mitte
    Leipzig, 04103, Germany
  • University Of Mainz Medical Center
    Mainz, 55131, Germany
  • Klinikum reechts der Isar, Technical University Munchen
    Munich, 81675, Germany
  • HPG23
    Bergamo, 24127, Italy
  • Fondazione Irccs Istituto Nazionale Tumori
    Milan, 20133, Italy
  • Irccs Istituto Oncologico Veneto Iov
    Padova, 35128, Italy
  • Aichi Clinical Site
    Nagoya, Aichi 464-8681, Japan
  • Aichi Clinical Site
    Nagoya, Aichi 466-8560, Japan
  • Aomori Clinical Site
    Hirosaki, Aomori 036-8563, Japan
  • Chiba Clinical Site
    Kashiwa, Chiba 277-8577, Japan
  • Ehime Clinical Site
    Matsuyama, Ehime 791-0288, Japan
  • Hokkaido Clinical Site
    Sapporo, Hokkaido 003-0027, Japan
  • Hokkaido Clinical Site
    Sapporo, Hokkaido 060-8648, Japan
  • Hyogo Clinical Site
    Akashi, Hyogo 673-0021, Japan
  • Hyogo Clinical Site
    Kobe, Hyogo 650-0047, Japan
  • Kanagawa Clinical Site
    Isehara, Kanagawa 259-1193, Japan
  • Kanagawa Clinical Site
    Kawasaki, Kanagawa 216-0015, Japan
  • Kanagawa Clinical Site
    Yokohama, Kanagawa 236-0004, Japan
  • Kanagawa Clinical Site
    Yokohama, Kanagawa 241-8515, Japan
  • Mie Clinical Site
    Tsu, Mie 514-8507, Japan
  • Miyagi Clinical Site
    Sendai, Miyagi 980-8574, Japan
  • Nagano Clinical Site
    Saku, Nagano 385-0051, Japan
  • Niigata Clinical Site
    Nigatake, Niigata 951-8520, Japan
  • Osaka Clinical Site
    Osakasayama, Osaka 589-8511, Japan
  • Osaka Clinical Site
    Suita, Osaka 565-0871, Japan
  • Osaka Clinical Site
    Takatsuki, Osaka 569-0801, Japan
  • Saitama Clinical Site
    Hidaka, Saitama 350-1298, Japan
  • Saitama Clinical Site
    Kita-Adachi County, Saitama 362-0806, Japan
  • Shizuoka Clinical Site
    Suntou County, Shizuoka 411-8777, Japan
  • Tochigi Clinical Site
    Shimotsuke, Tochigi 329-0431, Japan
  • Tokyo Clinical Site
    Bunkyo-ku, Tokyo 113-0021, Japan
  • Tokyo Clinical Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Tokyo Clinical Site
    Chuo-ku, Tokyo 104-8560, Japan
  • Tokyo Clinical Site
    Koto-ku, Tokyo 135-8550, Japan
  • Tokyo Clinical Site
    Meguro-ku, Tokyo 152-8902, Japan
  • Tokyo Clinical Site
    Minato-ku, Tokyo 105-8470, Japan
  • Tokyo Clinical Site
    Shinagawa-ku, Tokyo 142-8666, Japan
  • Tokyo Clinical Site
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Tokyo Clinical Site
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Akita Clinical Site
    Akita, 010-8543, Japan
  • Chiba Clinical Site
    Chiba, 260-0801, Japan
  • Chiba Clinical Site
    Chiba, 260-8677, Japan
  • Fukuoka Clinical Site
    Fukuoka, 812-8582, Japan
  • Fukushima Clinical Site
    Fukushima, 960-1295, Japan
  • Hiroshima Clinical Site
    Hiroshima, 734-8551, Japan
  • Kagoshima Clinical Site
    Kagoshima, 890-8520, Japan
  • Kumamoto Clinical Site
    Kumamoto, 860-8556, Japan
  • Kyoto Clinical Site
    Kyoto, 602-8566, Japan
  • Kyoto Clinical Site
    Kyoto, 606-8507, Japan
  • Niigata Clinical Site
    Niigata, 951-8566, Japan
  • Osaka Clinical Site
    Osaka, 537-8511, Japan
  • Shizuoka Clinical Site
    Shizuoka, 420-8527, Japan
  • Busan Clinical Site
    Busan, 49241, Korea, Republic of
  • Daegu Clinical Site
    Daegu, 41404, Korea, Republic of
  • Daegu Clinical Site
    Daegu, 41931, Korea, Republic of
  • Daejeon Clinical Site
    Daejeon, 35015, Korea, Republic of
  • Gyeonggi-do Clinical Site
    Gyeonggi-do, 13620, Korea, Republic of
  • Hwasun-Gun Clinical Site
    Hwasun-Gun, 58128, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 03080, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 03722, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 05505, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 06351, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 06591, Korea, Republic of
  • Ulsan Clinical Site
    Ulsan, 44033, Korea, Republic of
  • Changhua Clinical Site
    Changhua, 500, Taiwan
  • Chiayi Clinical Site
    Chiayi, 61363, Taiwan
  • Kaohsiung Clinical Site
    Kaohsiung, 807, Taiwan
  • Kaohsiung Clinical Site
    Kaohsiung, 82445, Taiwan
  • Kaohsiung Clinical Site
    Kaohsiung, 83301, Taiwan
  • Keelung Clinical Site
    Keelung, 20445, Taiwan
  • Taichung Clinical Site
    Taichung, 40447, Taiwan
  • Tainan Clinical Site
    Tainan, 704, Taiwan
  • Taipei Clinical Site
    Taipei, 10048, Taiwan
  • Taipei Clinical Site
    Taipei, 11217, Taiwan
  • Taoyuan Clinical Site
    Taoyuan, 333, Taiwan
  • Velindre Cancer Centre
    Cardiff, Cardiganshire CF142TL, United Kingdom
  • The Beatson West Of Scotland Cancer Centre
    Glasgow, Lanarkshire G12 0YN, United Kingdom
09

References and documents

Publications

  • Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Erratum In: Lancet Oncol. 2019 Nov;20(11):e613. doi: 10.1016/S1470-2045(19)30646-1. PubMed 31582355 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Data sharing details ↗ · www.ono.co.jp

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Oct 2020, 58 months.

Results were first posted in Jan 2022, 1 year 2 months after primary completion.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's 58 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2015
First posted
Oct 6, 2015
StartActual
Dec 14, 2015
Primary completionActual
Oct 23, 2020
CompletionActual
Oct 23, 2020
Results first posted
Jan 14, 2022
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02569242
Responsible party
Sponsor
First posted
Oct 6, 2015
Start date
Dec 14, 2015
Primary completion
Oct 23, 2020
Completion
Oct 23, 2020
Results posted
Jan 14, 2022
Last update
Jul 6, 2022

Study contacts

Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd.
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion